To investigate the exact relationship between CT tumor size and the microscopic tumor size in PDAC.We enrolled 310 patients with pathologically confirmed PDAC without preoperative adjuvant therapies who underwent CT examination from June 2016 and December 2018. Smooth curve fitting and a segmented regression model were used to analyze the threshold effect between CT tumor size and the microscopic tumor size.The tumor size was 2.93±1.15 cm under the microscope and 3.00±1.23 cm in CT. The mean bias was 0.067 cm between CT and microscopic assessments. The accuracy of CT T stages was 61.02% (36/59), 79.41% (162/204) and 57.45% (27/47) in T1, T2 and T3, respectively. A non-linear relationship was detected between CT tumor size and the microscopic tumor size, with a turning point of 4.3 cm. On the left of the inflection point, the effect size, 95% confidence interval, and p value were 0.51, 0.40 to 0.63, and <0.0001, respectively. However, we observed no relationship between CT size and microscopic tumor size on the right of the inflection point (0.22, 0 to 0.44, 0.053).The relationship between CT and the microscopic tumor size is non-linear. When the CT tumor size was <4.3 cm, every 1-cm increase in CT tumor size was associated with a 0.56 cm increase in microscopic tumor size. When the CT tumor size was >4.3 cm, every 1-cm increase in CT tumor size was associated with a 0.91 cm increase in microscopic tumor size.Copyright © 2020 Elsevier Inc. All rights reserved.

Intraductal papillary mucinous neoplasms (IPMNs) are radiographically visible precursor lesions of pancreatic cancer. Despite standard criteria for assessing risk, only 18% of cysts are malignant at resection. Thus, a large number of patients undergo unnecessary invasive surgery for benign disease. The ability to identify IPMNs with low or high risk of transforming into invasive cancer would optimize patient selection and improve surgical decision-making. The purpose of this study was to investigate quantitative CT imaging features as markers for objective assessment of IPMN risk.This retrospective study analyzed pancreatic cyst and parenchyma regions extracted from CT scans in 103 patients to predict IPMN risk. Patients who underwent resection between 2005 and 2015 with pathologically proven branch duct (BD)-IPMN and a preoperative CT scan were included in the study. Expert pathologists categorized IPMNs as low or high risk following resection as part of routine clinical care. We extracted new radiographically inspired features as well as standard texture features and designed prediction models for the categorization of high- and low-risk IPMNs. Five clinical variables were also combined with imaging features to design prediction models.Using images from 103 patients and tenfold cross-validation technique, the novel radiographically inspired imaging features achieved an area under the receiver operating characteristic curve (AUC) of 0.77, demonstrating their predictive power. The combination of these features with clinical variables obtained the best performance (AUC = 0.81).The present study demonstrates that features extracted from pretreatment CT images can predict the risk of IPMN. Development of a preoperative model to discriminate between low-risk and high-risk IPMN will improve surgical decision-making.© 2018 American Association of Physicists in Medicine.

Radiomics is an emerging area in quantitative image analysis that aims to relate large-scale extracted imaging information to clinical and biological endpoints. The development of quantitative imaging methods along with machine learning has enabled the opportunity to move data science research towards translation for more personalized cancer treatments. Accumulating evidence has indeed demonstrated that noninvasive advanced imaging analytics, that is, radiomics, can reveal key components of tumor phenotype for multiple three-dimensional lesions at multiple time points over and beyond the course of treatment. These developments in the use of CT, PET, US, and MR imaging could augment patient stratification and prognostication buttressing emerging targeted therapeutic approaches. In recent years, deep learning architectures have demonstrated their tremendous potential for image segmentation, reconstruction, recognition, and classification. Many powerful open-source and commercial platforms are currently available to embark in new research areas of radiomics. Quantitative imaging research, however, is complex and key statistical principles should be followed to realize its full potential. The field of radiomics, in particular, requires a renewed focus on optimal study design/reporting practices and standardization of image acquisition, feature calculation, and rigorous statistical analysis for the field to move forward. In this article, the role of machine and deep learning as a major computational vehicle for advanced model building of radiomics-based signatures or classifiers, and diverse clinical applications, working principles, research opportunities, and available computational platforms for radiomics will be reviewed with examples drawn primarily from oncology. We also address issues related to common applications in medical physics, such as standardization, feature extraction, model building, and validation.© 2019 American Association of Physicists in Medicine.

To evaluate the diagnostic performance of the radiomics score (rad-score) for differentiating focal-type autoimmune pancreatitis (fAIP) from pancreatic ductal adenocarcinoma (PDAC).This retrospective review included 42 consecutive patients with fAIP diagnosed according to the International Consensus Diagnostic Criteria between January 2011 and December 2018. Furthermore, 334 consecutive patients with PDAC confirmed by pathology were also reviewed during the same period. Patients with PDAC and fAIP were matched via propensity score matching (PSM). All patients underwent multidetector computed tomography (MDCT). For each patient, 1409 radiomics features of the portal phase were extracted and reduced using the least absolute shrinkage and selection operator (LASSO) logistic regression algorithm. The portal rad-score performance was assessed based on its discriminative ability.After PSM, we matched 55 patients with PDAC to 42 patients with fAIP, based on clinical and CT characteristics (e.g., patient age, sex, body mass index, location, size, enhanced mode). A rad-score for discriminating fAIP from PDAC, which contained four CT derived radiomic features, was developed (area under the curve = 0.97). The sensitivity, specificity, and accuracy of the radiomics model were 95.24%, 92.73% and 0.94, respectively.The portal rad-score can accurately and noninvasively differentiate fAIP from PDAC.Copyright © 2021 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

As the most lethal major cancer, pancreatic cancer is a global healthcare challenge. Personalized medicine utilizing cutting-edge multi-omics data holds potential for major breakthroughs in tackling this critical problem. Radiomics and deep learning, two trendy quantitative imaging methods that take advantage of data science and modern medical imaging, have shown increasing promise in advancing the precision management of pancreatic cancer via diagnosing of precursor diseases, early detection, accurate diagnosis, and treatment personalization and optimization. Radiomics employs manually-crafted features, while deep learning applies computer-generated automatic features. These two methods aim to mine hidden information in medical images that is missed by conventional radiology and gain insights by systematically comparing the quantitative image information across different patients in order to characterize unique imaging phenotypes. Both methods have been studied and applied in various pancreatic cancer clinical applications. In this review, we begin with an introduction to the clinical problems and the technology. After providing technical overviews of the two methods, this review focuses on the current progress of clinical applications in precancerous lesion diagnosis, pancreatic cancer detection and diagnosis, prognosis prediction, treatment stratification, and radiogenomics. The limitations of current studies and methods are discussed, along with future directions. With better standardization and optimization of the workflow from image acquisition to analysis and with larger and especially prospective high-quality datasets, radiomics and deep learning methods could show real hope in the battle against pancreatic cancer through big data-based high-precision personalization.

The accurate classification between malignant and benign breast lesions detected on mammograms is a crucial but difficult challenge for reducing false-positive recall rates and improving the efficacy of breast cancer screening. This study aims to optimize a new deep transfer learning model by implementing a novel attention mechanism in order to improve the accuracy of breast lesion classification. ResNet50 is selected as the base model to develop a new deep transfer learning model. To enhance the accuracy of breast lesion classification, we propose adding a convolutional block attention module (CBAM) to the standard ResNet50 model and optimizing a new model for this task. We assembled a large dataset with 4280 mammograms depicting suspicious soft-tissue mass-type lesions. A region of interest (ROI) is extracted from each image based on lesion center. Among them, 2480 and 1800 ROIs depict verified benign and malignant lesions, respectively. The image dataset is randomly split into two subsets with a ratio of 9:1 five times to train and test two ResNet50 models with and without using CBAM. Using the area under ROC curve (AUC) as an evaluation index, the new CBAM-based ResNet50 model yields AUC = 0.866 ± 0.015, which is significantly higher than that obtained by the standard ResNet50 model (AUC = 0.772 ± 0.008) (&lt; 0.01). This study demonstrates that although deep transfer learning technology attracted broad research interest in medical-imaging informatic fields, adding a new attention mechanism to optimize deep transfer learning models for specific application tasks can play an important role in further improving model performances.

Preoperative prediction of pancreatic cystic neoplasm (PCN) differentiation has significant value for the implementation of personalized diagnosis and treatment plans. This study aimed to build radiomics deep learning (DL) models using computed tomography (CT) data for the preoperative differential diagnosis of common cystic tumors of the pancreas.Clinical and CT data of 193 patients with PCN were collected for this study. Among these patients, 99 were pathologically diagnosed with pancreatic serous cystadenoma (SCA), 55 were diagnosed with mucinous cystadenoma (MCA) and 39 were diagnosed with intraductal papillary mucinous neoplasm (IPMN). The regions of interest (ROIs) were obtained based on manual image segmentation of CT slices. The radiomics and radiomics-DL models were constructed using support vector machines (SVMs). Moreover, based on the fusion of clinical and radiological features, the best combined feature set was obtained according to the Akaike information criterion (AIC) analysis. Then the fused model was constructed using logistic regression.For the SCA differential diagnosis, the fused model performed the best and obtained an average area under the curve (AUC) of 0.916. It had a best feature set including position, polycystic features (≥6), cystic wall calcification, pancreatic duct dilatation and radiomics-DL score. For the MCA and IPMN differential diagnosis, the fused model with AUC of 0.973 had a best feature set including age, communication with the pancreatic duct and radiomics score.The radiomics, radiomics-DL and fused models based on CT images have a favorable differential diagnostic performance for SCA, MCA and IPMN. These findings may be beneficial for the exploration of individualized management strategies.© 2022. The Author(s).

To investigate the value of CT-based radiomics analysis in preoperatively discriminating pancreatic mucinous cystic neoplasms (MCN) and atypical serous cystadenomas (ASCN).